Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag as First-line Treatment in Newly Diagnosed Elderly ITP Patients
NCT05311930Phase 4Unknown
- Start
- May 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of hetrombopag in primary immune thrombocytopenia (ITP). Primary endpoint: Treatment response at 28 days. Status: unknown.
02
Drugs
hetrombopag
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05311930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05311930.